Cencora Stock Drops 5.92% as Walgreens Shifts Business Volume to Competitors

Key Facts

Amid intensifying competition in the pharmaceutical distribution sector, Cencora faced sharp selling pressure that significantly impacted its market valuation. Cencora stock closed down 5.92% on August 12 following confirmation that non-prime pharmaceutical volume associated with Walgreens is transitioning to competing distributors. This disclosure rattled investor confidence regarding revenue risks and customer retention, even as management emphasized that the core prime vendor agreement with Walgreens remains fully intact and represents the vast majority of their commercial relationship.

In contrast to the decline in Cencora, the broader healthcare sector remained relatively stable according to market data, with peers showing mixed performance. While Unitedhealth Group rose 0.85% and Boston Scientific gained 0.44%, Intuitive Surgical saw a marginal decline of 0.08%. This divergence suggests that the selling pressure was specifically concentrated on Cencora due to the confirmed loss of business volume rather than reflecting a broader weakness in healthcare indexes or macroeconomic conditions.

Regarding current price levels, the 0HF3.L instrument was priced at 324.34 USD at the close of August 10, 2026, with a daily range between 318.05 USD and 326.01 USD. Traders will be watching for the company's ability to protect margins despite rising interest expenses and asset impairments that weighed on sentiment. With no major upcoming corporate events in the immediate calendar, market focus remains on the stability of the remaining sales volume with Walgreens.